## RECEIVED **CENTRAL FAX CENTER**

JUN. 30. 2005 10:59AM AVENTIS US PAT DEPT TO: US USPTO GENERAL

Signature

Typed or printed name

Paul Irvine

JUN 3 0 2005

NO. 6476 P. 1

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0051 U.S. Petent and Tradomark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/035,783 TRANSMITTAL Filing Date December 24, 2001 First Named Inventor FORM Michael GRAUPE et al. Art Unit 1626 Examiner Name CUIAO Bai Tanna

(to be used for all correspondence after initial filing)		Jilko, Her isang		O, riei isang
Total Number of Pages in This Submission	24	Attorney Docket Number	USAV	/2001/0081 US NP
ENCLOSURES (Check all that apply)				
ENCLOSURES (Check all that apply)				
Fee Transmiltal Form Fee Attached		Drawing(s) Licensing-related Papers		After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences
Amendment/Reply After Final Affidavits/declaration(s)  Extension of Time Request Express Abandonment Request Information Disclosure Statement		Petition Petition to Convert to a Provisional Application Power of Attorney, Revocati Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	Address	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53	Remar	rks .		RECEIVED OIPE/IAP JUL 0 1 2005
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT				
AVENTIS PHARMACEUTICALS INC.				
Signature They O				
Printed name  Joseph ROSS				
Date June 30, 2005			Reg. No.	47038
CERTIFICATE OF TRANSMISSION/MAILING				
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Palents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 ; Total No. of Pages Transmitted: 244 )				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pattent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

June 30, 2005

JUN. 30. 2005 10:59AM

AVENTIS US PAT DEPT

RECEIVED **CENTRAL FAX CENTER** JUN 3 0 2005

NO. 6476

USAV2001/0081 US NP

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GRAUPE, et al.

Examiner:

Robert SHIAO

Art Unit:

1626

Application No.: 10/035,783

TELEPAX CERTIFICATE

Filed: December 24, 2001

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

Title: NOVEL COMPOUNDS AND COMPOSITIONS

AS CATHEPSIN INHIBITORS

June 30, 2005

## REPLY PUSUANT TO 37 C.F.R. § 1.111

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated February 2, 2005 ("the Action"), reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.
- Remarks/Arguments begin on page 21 of this paper.

Filed concurrently herewith is a Petition for Extension of Time pursuant to 37 C.F.R. § 1.136(a) for two (2) months.